Brief Alcohol Withdrawal Scale (BAWS)
5-item Brief Alcohol Withdrawal Scale (tremor, sweats, agitation, confusion/orientation, hallucinations; each 0–3, total 0–15) for symptom-triggered treatment (Rastegar 2017). BAWS ≥ 3 triggers treatment.
Score interpretation
Below the BAWS treatment threshold
→ Reassess every 4–6 h. Oral hydration, close monitoring; consider PRN benzodiazepine; no routine scheduled benzodiazepines needed. Adults: thiamine 100 mg IM/IV. Children: use a children's formulary.
Withdrawal at the BAWS treatment threshold
→ Symptom-triggered benzodiazepine per local protocol, reassessing every 4 h until BAWS < 3. Adults: thiamine 200–500 mg IV. Children: use a children's formulary.
Severe alcohol withdrawal (BAWS ≥ 6); delirium tremens risk
→ Benzodiazepine every 2 h until BAWS < 6 and notify the physician if > 8 (BAWS protocol). Medical emergency: HDU/ICU admission; seizure precautions; correct electrolytes (Mg, K, phosphate). Adults: IV benzodiazepines (diazepam 10 mg IV PRN, titrated); thiamine 500 mg IV TDS × 3 days. Children: use a children's formulary.
Interpretation bands for the BAWS. Apply clinical judgement and local guidance.
References
- Rastegar DA, et al. Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS). Subst Abus. 2017;38(4):394–400.
- Rastegar DA, et al. Implementation of a protocol using the 5-item Brief Alcohol Withdrawal Scale for treatment of severe alcohol withdrawal in intensive care units. J Intensive Care Med. 2021;36(11):1361–1365.
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.